公开(公告)号：EP0769961B1

公开(公告)日：2006-11-02

申请号：EP95926645.3

申请日：1995-07-07

申请人： Biomarin Pharmaceutical Inc.

发明人： ZIMMERMANN, Joseph ,  VLODAVSKY, Israel ,  BENNETT, D., Clark ,  DANAGHER, Pamela ,  BROUGHTON, Richard

IPC分类号： A61K38/51 ,  A61P17/02

CPC分类号： A61K38/51 ,  Y10S530/825

摘要： Glycosaminoglycans, including heparinases 1, 2 and 3 as well as chondroitinases AC and B from the Gram negative bacteria Flavobacterium heparinum, can be used either separately or in combination to manipulate cell proliferation. In one embodiment, heparinases are administered to degrade heparan sulfate components of the extracellular matrix, thereby allowing the heparin binding growth factors which are stored in the extracellular matrix to migrate to adjacent cells. The mobility of chemoattractant agents, growth factors and cells also can be increased by treating tissues with glycosaminoglycan degrading enzymes, both chondroitinases and heparinases. The enzymatic removal of chondroitin sulfates from cell surfaces effectively increases the availability of growth factor receptors on the cell's surface. Selectively removing heparan sulfate from cell surfaces while leaving the extracellular matrix intact, conversely, inhibits cell proliferation by down regulating the cell's response to growth factors. This is achieved by targeting heparin or heparan sulfate degrading activites to the cell surface. Targeting the heparin degrading activity can be achieved by genetically engineering a ligand binding functionality into the heparinase proteins, or by physically controlling the localized enzyme concentration through the method of administration.